Welcome to our dedicated page for Tradewinds Unvl SEC filings (Ticker: TRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tradewinds Universal, Inc. (TRWD) SEC filings page on Stock Titan is designed to help investors review the company’s regulatory disclosures in one place. Tradewinds describes itself as a fully reporting, publicly traded holding company on the OTC Markets platform, emphasizing SEC and PCAOB compliance as it builds an adult hospitality and entertainment division alongside other consumer-focused holdings.
For a company with an acquisition-driven model, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q, when available, can provide detail on segment focus, acquisition structures, and risk factors associated with adult nightlife and hospitality operations. Current reports on Form 8-K, where filed, may outline material events such as agreements with Peppermint Hippo, progress on staged acquisitions, or changes in board composition and governance that support the company’s consolidation strategy.
Investors interested in governance and ownership dynamics can also look to proxy materials and, where applicable, beneficial ownership or insider transaction reports such as Form 4 to understand how management and directors are aligned with the business. Tradewinds’ public statements highlight plans to expand its board with expertise in finance, licensing, real estate, and hospitality operations, making governance-related filings particularly relevant.
On Stock Titan, TRWD filings are paired with AI-powered summaries that explain the key points of each document in accessible language. These tools are intended to help readers quickly identify how new filings relate to Tradewinds Universal’s stated goals of consolidating adult hospitality venues, applying its Rebuild → Rebrand → Relaunch framework, and maintaining transparent reporting as a fully reporting OTC holding company.
Tradewinds Universal is registering 20,000,000 shares of common stock for resale by RH2 Equity Partners under a committed equity facility. The company itself is not selling shares in this prospectus, but may sell up to $10,000,000 of stock to RH2 at its discretion over 24 months.
As of December 31, 2025, Tradewinds had 42,690,580 shares outstanding and operates edible insect protein products and a licensed canine pain-relief formula, while exploring a nightlife and hospitality expansion via a non-binding Peppermint Hippo LOI. 2025 revenue was $133,222, with a net loss of $892,877, and auditors have raised substantial doubt about its ability to continue as a going concern.
The filing highlights very early-stage operations, heavy reliance on CEO Andrew Read, liquidity risk, penny-stock trading on OTCMarkets under “TRWD,” and the potential for significant dilution and price pressure as RH2 resells shares purchased at a discount to market.
Tradewinds Universal, Inc. reports a larger 2025 loss and files an amended annual report to add auditor consent without changing prior disclosures. Revenue fell to about $133,222, mainly from licensing and distribution rights, down from $171,596 in 2024 as it exited physical product sales.
Operating expenses jumped to roughly $1,026,099, driven by about $886,105 in consulting and professional costs, leading to a net loss of approximately $892,877 and an accumulated deficit near $1,183,067. Cash stood at $16,638 within total assets of about $307,333, and auditors highlighted substantial doubt about the company’s ability to continue as a going concern. The company shifted toward licensing, acquired additional intangible assets, and secured a $10.0 million common stock purchase agreement to access future equity financing.
Tradewinds Universal, Inc. reported that its recently filed Annual Report on Form 10-K for the year ended December 31, 2025 did not include a required auditor consent. The missing consent relates to the report of Astra Audit & Advisory, the company’s independent registered public accounting firm for December 31, 2024.
The company is working with Astra Audit & Advisory to obtain this consent as promptly as practicable. Once received, it plans to file the consent with the SEC and may amend the 2025 Form 10-K solely to add the consent. The company is also evaluating how the omitted consent affects any effective registration statements that incorporate the original Form 10-K by reference.
Tradewinds Universal reported 2025 revenue of $133,222, down from $171,596 in 2024, as it shifted away from physical protein bar sales toward licensing and distribution rights. With no cost of goods sold, gross margin reached 100%, but operating expenses surged to $1,026,099, driven mainly by consulting and stock-based compensation.
The company recorded a 2025 net loss of $892,877 and ended the year with total assets of $307,333, including $216,500 in intangible assets, and cash of $16,638. Accumulated deficit rose to $1,183,067, and auditors highlighted substantial doubt about its ability to continue as a going concern.
Strategically, Tradewinds is focusing on licensing its canine pain relief formula, selling distribution and licensing rights, and pursuing new verticals. In August 2025 it signed a Letter of Intent with Peppermint Hippo™ to enter the nightlife and hospitality sector. Subsequent to year-end, it entered a $10.0 million common stock purchase agreement with RH2 Equity Partners to provide potential future equity funding.
Tradewinds Universal notified the SEC that its Annual Report on Form 10-K for the period ended December 31, 2025 will be filed late. The company says it needs additional time "for compilation and review to insure adequate disclosure" and states the report "will be filed on or before the 15th calendar day following the prescribed due date." The notification is signed by CEO Andrew Read on March 31, 2026.
Tradewinds Universal has filed an S-1 to register the resale of up to 20,000,000 shares of common stock by RH2 Equity Partners under a committed equity facility. The company itself is not selling shares in this prospectus, but may raise up to $10,000,000 by selling stock to RH2 at its discretion under a separate purchase agreement.
As of January 29, 2026, Tradewinds had 43,690,580 common shares outstanding, trading on OTCMarkets under the symbol TRWD at $0.10 per share. The company is an early-stage holding company built around insect-protein nutrition products and a canine pain-relief formula, and has signed a letter of intent to expand into nightlife and hospitality through Peppermint Hippo-branded venues.
The filing highlights limited operating history, recurring net losses, tight liquidity, dependence on CEO Andrew Read, and significant potential dilution from equity financing. Shares are classified as penny stock, which can reduce trading liquidity and make it harder for investors to resell their holdings.
Tradewinds Universal (TRWD) filed its Q3 2025 10‑Q, reporting higher quarterly sales but a larger loss and a going‑concern warning. Q3 sales were $65,450 versus $28,068 a year ago, driven by distribution rights. Q3 net loss widened to $108,199 from $36,547 as consulting and professional fees rose.
For the nine months, sales were $98,422 versus $146,179 last year, reflecting the shift away from UP protein bar product sales and affiliate commissions. Nine‑month net loss was $134,454 compared to $102,249. Cash was $7,161 at September 30, 2025. Total assets increased to $316,556, mainly from $222,700 of intangible assets (including a $200,000 AI application acquired for 173,913 shares). Stockholders’ equity was $312,056.
The company disclosed substantial doubt about its ability to continue as a going concern and noted disclosure controls were not effective as of September 30, 2025. Shares outstanding were 36,610,580 as of November 14, 2025. Management highlighted an August 2025 LOI with Peppermint Hippo to enter nightlife and hospitality, starting with the planned acquisition of Peppermint Hippo Toledo.